JP2020203894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020203894A5 JP2020203894A5 JP2020135954A JP2020135954A JP2020203894A5 JP 2020203894 A5 JP2020203894 A5 JP 2020203894A5 JP 2020135954 A JP2020135954 A JP 2020135954A JP 2020135954 A JP2020135954 A JP 2020135954A JP 2020203894 A5 JP2020203894 A5 JP 2020203894A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- cardiac
- deletion
- seq
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022178566A JP2023025005A (ja) | 2013-01-17 | 2022-11-08 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2025092726A JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13151593 | 2013-01-17 | ||
| EP13151593.4 | 2013-01-17 | ||
| JP2015553072A JP6809789B2 (ja) | 2013-01-17 | 2014-01-16 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553072A Division JP6809789B2 (ja) | 2013-01-17 | 2014-01-16 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178566A Division JP2023025005A (ja) | 2013-01-17 | 2022-11-08 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020203894A JP2020203894A (ja) | 2020-12-24 |
| JP2020203894A5 true JP2020203894A5 (enExample) | 2025-02-04 |
| JP7685737B2 JP7685737B2 (ja) | 2025-05-30 |
Family
ID=47559322
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553072A Active JP6809789B2 (ja) | 2013-01-17 | 2014-01-16 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2020135954A Active JP7685737B2 (ja) | 2013-01-17 | 2020-08-11 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2022178566A Pending JP2023025005A (ja) | 2013-01-17 | 2022-11-08 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2025092726A Pending JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553072A Active JP6809789B2 (ja) | 2013-01-17 | 2014-01-16 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178566A Pending JP2023025005A (ja) | 2013-01-17 | 2022-11-08 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
| JP2025092726A Pending JP2025143268A (ja) | 2013-01-17 | 2025-06-03 | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10369198B2 (enExample) |
| EP (2) | EP3747457A3 (enExample) |
| JP (4) | JP6809789B2 (enExample) |
| CN (6) | CN110903378A (enExample) |
| CA (1) | CA2898128A1 (enExample) |
| DK (1) | DK2945642T3 (enExample) |
| ES (1) | ES2986021T3 (enExample) |
| FI (1) | FI2945642T3 (enExample) |
| HR (1) | HRP20240623T1 (enExample) |
| HU (1) | HUE068364T2 (enExample) |
| LT (1) | LT2945642T (enExample) |
| PL (1) | PL2945642T3 (enExample) |
| PT (1) | PT2945642T (enExample) |
| RS (1) | RS65553B1 (enExample) |
| SI (1) | SI2945642T1 (enExample) |
| WO (1) | WO2014111458A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014111458A2 (en) * | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
| EP4005585B1 (en) | 2013-11-21 | 2024-03-27 | The Brigham & Women's Hospital, Inc. | Compositions and methods for treating right ventricular hypertrophy |
| CA2956256A1 (en) * | 2014-08-01 | 2016-02-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| US10435757B1 (en) | 2016-06-15 | 2019-10-08 | University Of South Florida | Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof |
| CN108802372B (zh) * | 2018-06-19 | 2021-05-11 | 上海伦泽生物科技有限公司 | 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒 |
| CN115698048A (zh) | 2020-01-21 | 2023-02-03 | 勃林格殷格翰国际有限公司 | 用于治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 |
| CN114149500B (zh) * | 2020-09-07 | 2023-12-01 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用 |
| CN114149498B (zh) * | 2020-09-07 | 2023-12-05 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体在防治2型糖尿病中的应用 |
| CN114149499B (zh) * | 2020-09-07 | 2023-12-05 | 复旦大学附属华山医院 | 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用 |
| EP4267594A1 (en) | 2020-12-23 | 2023-11-01 | Boehringer Ingelheim International GmbH | Viral capsid proteins with specificity to heart tissue cells |
| AU2022307365A1 (en) * | 2021-07-08 | 2024-02-01 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
| KR20250031229A (ko) | 2022-06-03 | 2025-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 골수 유래된 성장 인자의 재조합 발현 |
| WO2024052563A1 (en) | 2022-09-08 | 2024-03-14 | Boehringer Ingelheim International Gmbh | Myeloid-derived growth factor for use in treating cardiogenic shock |
| TW202528339A (zh) | 2023-09-01 | 2025-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療或預防肝臟病症之骨髓源性生長因子 |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| US20250186549A1 (en) | 2023-12-06 | 2025-06-12 | Boehringer Ingelheim International Gmbh | Novel formulation comprising myeloid-derived growth factor |
| CN120738287A (zh) * | 2025-07-03 | 2025-10-03 | 广州医科大学附属妇女儿童医疗中心 | 急性低灌注动物模型的构建方法及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3584341D1 (de) | 1984-08-24 | 1991-11-14 | Upjohn Co | Rekombinante dna-verbindungen und expression von polypeptiden wie tpa. |
| JP2002500502A (ja) | 1996-06-11 | 2002-01-08 | メルク エンド カンパニー インコーポレーテッド | 合成ｃ型肝炎遺伝子 |
| JP2001506484A (ja) * | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| CA2265923A1 (en) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | Human proteins having secretory signal sequences and dnas encoding these proteins |
| WO2002008284A2 (en) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2000073445A2 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Interleukin-1-receptor associated kinase-3 (irak3) |
| PL334902A1 (en) * | 1997-01-29 | 2000-03-27 | Cornell Res Foundation Inc | Repeatable local delivery of adenoviral vector in order to induce angiogenesis |
| DE60045243D1 (de) | 1999-05-26 | 2010-12-30 | Next Biomed Technologies Nbt Oy | VERFAHREN UND MATERIALIEN ZUR ERZEUGUNG VON SH3 DOMäNEN MIT ANGEPASSTEN BINDUNGSEIGENSCHAFTEN |
| WO2001012669A1 (en) * | 1999-08-16 | 2001-02-22 | Universita' Degli Studi Di Siena | Vegf-d and angiogenic use thereof |
| WO2002081681A1 (fr) * | 2001-03-30 | 2002-10-17 | Chugai Seiyaku Kabushiki Kaisha | Nouvelle utilisation de la cytokine sf20 |
| DE10119804A1 (de) * | 2001-04-23 | 2002-10-24 | Brahms Ag | Entzündungsspezifische Peptide und deren Verwendungen |
| WO2004060867A2 (en) | 2003-01-02 | 2004-07-22 | Timothy Kirk Gallaher | Secreted protein factor and cell membrane-bound splice variant |
| WO2004069173A2 (en) * | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US8486438B2 (en) | 2004-01-29 | 2013-07-16 | Brown University | Methods for progenitor cell recruitment and isolation |
| CN101160055A (zh) * | 2005-02-16 | 2008-04-09 | 莱蒂恩公司 | 慢病毒载体及其用途 |
| US20080004232A1 (en) * | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| EP2130547A1 (en) * | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| PE20121647A1 (es) * | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| US8735342B2 (en) | 2010-01-27 | 2014-05-27 | Neumedicines, Inc. | Method for treating brain cancer using a novel tumor suppressor gene and secreted factor |
| KR20120095063A (ko) * | 2011-02-18 | 2012-08-28 | 가톨릭대학교 산학협력단 | ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
| WO2014111458A2 (en) * | 2013-01-17 | 2014-07-24 | Medizinische Hochschule Hannover | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases |
-
2014
- 2014-01-16 WO PCT/EP2014/050788 patent/WO2014111458A2/en not_active Ceased
- 2014-01-16 LT LTEPPCT/EP2014/050788T patent/LT2945642T/lt unknown
- 2014-01-16 SI SI201432073T patent/SI2945642T1/sl unknown
- 2014-01-16 PT PT147008726T patent/PT2945642T/pt unknown
- 2014-01-16 CN CN201911137855.8A patent/CN110903378A/zh active Pending
- 2014-01-16 US US14/759,852 patent/US10369198B2/en active Active
- 2014-01-16 ES ES14700872T patent/ES2986021T3/es active Active
- 2014-01-16 CA CA2898128A patent/CA2898128A1/en active Pending
- 2014-01-16 CN CN201911124174.8A patent/CN110894226A/zh active Pending
- 2014-01-16 DK DK14700872.6T patent/DK2945642T3/da active
- 2014-01-16 CN CN201911137854.3A patent/CN110922468B/zh active Active
- 2014-01-16 CN CN201911137853.9A patent/CN111100197B/zh active Active
- 2014-01-16 JP JP2015553072A patent/JP6809789B2/ja active Active
- 2014-01-16 EP EP20178045.9A patent/EP3747457A3/en active Pending
- 2014-01-16 FI FIEP14700872.6T patent/FI2945642T3/fi active
- 2014-01-16 HR HRP20240623TT patent/HRP20240623T1/hr unknown
- 2014-01-16 CN CN201480005079.5A patent/CN104968361B/zh active Active
- 2014-01-16 HU HUE14700872A patent/HUE068364T2/hu unknown
- 2014-01-16 CN CN201911138039.9A patent/CN110922467A/zh active Pending
- 2014-01-16 PL PL14700872.6T patent/PL2945642T3/pl unknown
- 2014-01-16 EP EP14700872.6A patent/EP2945642B1/en active Active
- 2014-01-16 RS RS20240548A patent/RS65553B1/sr unknown
-
2020
- 2020-08-11 JP JP2020135954A patent/JP7685737B2/ja active Active
-
2022
- 2022-11-08 JP JP2022178566A patent/JP2023025005A/ja active Pending
-
2025
- 2025-06-03 JP JP2025092726A patent/JP2025143268A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020203894A5 (enExample) | ||
| JP2022115876A5 (enExample) | ||
| JP2023025005A5 (enExample) | ||
| US8435535B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| JP2019526580A5 (enExample) | ||
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| JP2024177497A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2020536489A5 (enExample) | ||
| JP2019521692A5 (enExample) | ||
| JP2020527167A5 (enExample) | ||
| JPWO2020205889A5 (enExample) | ||
| JP2021500880A5 (enExample) | ||
| JP2018516599A (ja) | ポックスウイルス由来のプロモーターおよびそれを含むベクター | |
| JP7642608B2 (ja) | ハンタウイルス抗原性組成物 | |
| JPWO2020223362A5 (enExample) | ||
| JPWO2020223356A5 (enExample) | ||
| JP2020535203A5 (enExample) | ||
| Lin et al. | Applications of Virus Vector–Mediated Gene Therapy in China | |
| JP4831551B2 (ja) | 非虚血性心筋障害に対する医薬 | |
| JPWO2020038473A5 (enExample) | ||
| CN117838832B (zh) | Rbm25及其相关物质在抗病毒感染中的应用 | |
| WO2022025178A1 (ja) | ＲＥＩＣ／Ｄｋｋ－３遺伝子を含むＥＧＦＲ遺伝子変異陽性肺癌の治療薬 | |
| JPWO2022010813A5 (enExample) | ||
| CN109306011A (zh) | 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途 |